FXS0887为集团(即公司及控股子公司/单位，下同)自主研发的口服小分子创新药物，拟用于治疗晚期恶 性实体瘤。FXS0887可特异性抑制ATR(Ataxia Telangiectasia and Rad3-related)激酶活性，通过干预细胞 周期调控和DNA损伤修复相关通路，从而抑制肿瘤细胞的恶性增殖。截至目前的临床前研究显示， FXS0887 在多种类型肿瘤模型中表现出良好的抗肿瘤活性，脱靶风险较小，安全性良好。 复星医药(600196.SH)发布公告，近日，公司控股子公司上海复星医药产业发展有限公司(以下简称"复星 医药产业")收到国家药品监督管理局关于同意FXS887片(项目代号及以下简称"FXS0887")用于晚期恶性 实体瘤开展临床试验的批准。复星医药产业拟于条件具备后于中国境内开展FXS0887的I期临床试验。 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-191 上海复星医药（集团）股份有限公司 关于控股子公司药品获临床试验批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公 司上海复星医药产业发展有限公司（以下简称"复星医药产业"）收到国家药品监督 管理局关于同意 FXS887 片（项目代号及以下简称"FXS0887"）用于晚期恶性实体瘤 开展临床试验的批准。复星医药产业拟于条件具备后于中国境内 1开展 FXS0887 的 I 期临床试验。 FXS0887 为本集团（即本公司及控股子公司/单位，下同）自主研发的口服小分 子创新药物，拟用于治疗晚期恶性实体瘤。FXS0887 可特异性抑制ATR（Ataxia Telangiectasia and Rad3-related）激酶活性，通过干预细胞周期调控和DNA损伤 修复相关通路，从而抑制肿瘤细胞的恶性增殖。截至目前的临床前研究显示，FXS0887 在多种类型肿瘤模型中表现出良好的抗 ...

FXS0887为集团(即公司及控股子公司/单位，下同)自主研发的口服小分子创新药物，拟用于治疗晚期恶 性实体瘤。FXS0887可特异性抑制ATR(Ataxia Telangiectasia and Rad3-related)激酶活性，通过干预细胞 周期调控和DNA损伤修复相关通路，从而抑制肿瘤细胞的恶性增殖。截至目前的临床前研究显示， FXS0887在多种类型肿瘤模型中表现出良好的抗肿瘤活性，脱靶风险较小，安全性良好。 复星医药（600196）(600196.SH)发布公告，近日，公司控股子公司上海复星医药产业发展有限公司(以 下简称"复星医药产业")收到国家药品监督管理局关于同意FXS887片(项目代号及以下简称"FXS0887")用 于晚期恶性实体瘤开展临床试验的批准。复星医药产业拟于条件具备后于中国境内开展FXS0887的I期 临床试验。 ...

Core Viewpoint - Fosun Pharma has received approval from the National Medical Products Administration for clinical trials of FXS887, an innovative oral small molecule drug aimed at treating advanced malignant solid tumors, with no similar drugs approved globally as of the announcement date [1] Company Summary - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is responsible for the development of FXS887 [1] - FXS887 is a self-developed drug by the company and its subsidiaries, indicating a strong focus on innovation in oncology [1] Industry Summary - The approval of FXS887 marks a significant milestone as there are currently no approved small molecule inhibitors targeting the same pathway for monotherapy or combination therapy in the global market [1]

FXS0887 为本集团（即本公司及控股子公司/单位，下同）自主研发的口服小分子创新药物，拟用于治 疗晚期恶性实体瘤。FXS0887 可特异性抑制ATR（AtaxiaTelangiectasia and Rad3-related）激酶活性，通 过干预细胞周期调控和DNA损伤修复相关通路，从而抑制肿瘤细胞的恶性增殖。截至目前的临床前研 究显示，FXS0887在多种类型肿瘤模型中表现出良好的抗肿瘤活性，脱靶风险较小，安全性良好。 格隆汇12月3日丨复星医药(600196.SH)公布，公司控股子公司上海复星医药产业发展有限公司（以下简 称"复星医药产业"）收到国家药品监督管理局关于同意 FXS887 片（项目代号及以下简称"FXS0887"） 用于晚期恶性实体瘤开展临床试验的批准。复星医药产业拟于条件具备后于中国境内开展FXS0887的I 期临床试验。 ...

证券代码：600196 证券简称：复星医药 公告编号：临 2025-190 上海复星医药（集团）股份有限公司 关于 2025 年 A 股股票期权激励计划 重要内容提示： ●A 股期权首次授予登记日：2025 年 12 月 2 日 ●A 股期权首次授予登记数量：4,446,400 份 根据《上海复星医药（集团）股份有限公司 2025 年 A 股股票期权激励计划》 （以下简称"2025 年 A 股期权计划"或"本次激励计划"）及上海复星医药（集 团）股份有限公司（以下简称"本公司"）2025 年第一次临时股东会的授权，本 次激励计划首次授予及登记工作已完成，现将相关事项公告如下： 一、本次激励计划首次授予情况 2025年11月4日，本公司第十届董事会第十四次会议审议通过关于2025年A 股期权计划首次授予相关事项的议案，董事会认为本次激励计划首次授予的条件 已经成就，同意以2025年11月4日作为首次授予日、向共计195名首次授予激励对 象授予合计4,535,100份A股期权，并办理该授予所需的相关事宜。该议案在提交 董事会审议前，已经董事会薪酬与考核委员会审核通过；董事会薪酬与考核委员 会亦对本次激励计划首次授 ...

每经AI快讯，12月3日，复星医药（600196）(600196.SH)公告称，控股子公司上海复星医药产业发展有 限公司(简称"复星医药产业")收到国家药品监督管理局关于同意FXS887片(简称"FXS0887")用于晚期恶 性实体瘤开展临床试验的批准。FXS0887为本集团(即本公司及控股子公司/单位)自主研发的口服小分子 创新药物，拟用于治疗晚期恶性实体瘤。截至本公告日期(即2025年12月3日)，于全球范围内尚无同靶 点的小分子抑制剂单药或联合治疗方案获批上市。 ...

Core Viewpoint - Fosun Pharma's subsidiary has received approval from the National Medical Products Administration for clinical trials of FXS887 for advanced malignant solid tumors, indicating a significant step in the company's oncology pipeline [1] Group 1: Clinical Development - The company plans to conduct Phase I clinical trials for FXS887 in China once conditions are met [1] - As of October 2025, the cumulative R&D investment for FXS887 is approximately RMB 44 million [1] - No other small molecule inhibitors targeting the same pathway have been approved globally for monotherapy or combination therapy [1]

Core Insights - The biopharmaceutical sector is one of the fastest-growing areas in the pharmaceutical industry, driven by an aging population and increased public health awareness [1][5] - China's biopharmaceutical market is projected to grow from CNY 312 billion in 2019 to CNY 587.1 billion in 2024, and is expected to reach CNY 675.2 billion by 2025, with a potential to hit CNY 1.149 trillion in the next five years [1][5][6] - Innovation remains the core driver of growth in the biopharmaceutical industry, which is capital-intensive and requires significant R&D investment [1][6] Industry Definition and Classification - Biopharmaceuticals are medical products manufactured using biological methods, aimed at replicating the activity of natural substances [2][4] - They can be categorized into vaccines, blood products, biopharmaceutical drugs, diagnostic reagents, and others, with further subdivisions based on source or mechanism of action [2] Current Industry Status - The global biopharmaceutical market is expected to grow from USD 286.4 billion in 2019 to USD 461.6 billion in 2024, with the original biopharmaceutical market projected to increase from USD 268.9 billion to USD 427.9 billion in the same period [5] - China plays a significant role in the global biopharmaceutical market, with rapid growth driven by favorable policies, increased R&D investment, and advancements in biotechnology [5][6] Industry Development Environment - Policies - The Chinese government has implemented various laws and policies to encourage biopharmaceutical R&D, including the Drug Registration Management Measures and regulations for clinical research and application of biomedical technologies [7] Competitive Landscape - The biopharmaceutical sector is recognized as a "new frontier" in the pharmaceutical industry, with major global players actively entering the market [9] - Key companies in China's biopharmaceutical industry include WuXi AppTec, Hengrui Medicine, ZhiFei Biological, BeiGene, and others, with a competitive landscape characterized by differentiated strategies [9] Future Development Trends - Market demand for biopharmaceuticals is expected to continue growing, supported by policy backing, technological advancements, and increased health awareness [10] - Domestic companies are transitioning from biosimilars to First-in-Class drugs, with examples like Hengrui Medicine's ADC drug showing superior efficacy [10][11] - Personalized medicine based on genetic testing is anticipated to become a trend, with increasing international recognition of Chinese innovative drugs [11]

Group 1 - The company held its second extraordinary general meeting of shareholders in 2025, with no resolutions being rejected [2][3] - The meeting was conducted in compliance with the Company Law and the company's articles of association, with a total of 2,639,554,073 shares eligible for voting [2][3] - The meeting was attended by 8 out of 11 directors, including the chairman and CEO, while 3 directors were absent due to other commitments [3] Group 2 - The company announced that its subsidiary, Suzhou Er Ye Pharmaceutical Co., Ltd., received acceptance for its drug registration application for Heparin Sodium Injection from the National Medical Products Administration [8] - The drug is intended for various medical uses, including the prevention and treatment of venous thromboembolism and anticoagulation during surgeries [9][10] - As of October 2025, the cumulative R&D investment for this drug was approximately RMB 8.61 million, with projected sales in China for 2024 estimated at RMB 1.386 billion [10] Group 3 - The company’s subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., received acceptance for its drug registration application for HLX14, a biosimilar of Denosumab [13] - HLX14 has been approved in the US and EU, with a cumulative R&D investment of approximately RMB 320 million as of the announcement date [15] - Global sales for Denosumab products are projected to be around USD 7.463 billion in 2024 [16] Group 4 - The company is involved in a private equity investment fund, the Dalian Star Future Fund, which focuses on investing in early-stage medical technology companies [20] - A recent agreement was made for a transfer of partnership shares within the fund, maintaining the company's shareholding percentage at 51% [21][23] - The new partner, Dalian Jinyun, has no prior relationship with the company and does not hold any shares in it [24]